February 15, 2024
OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer
January 4, 2024
OnKure Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for its Mutant Selective PI3Kα inhibitor, OKI-219
September 20, 2023
OnKure Therapeutics Appoints Ann Howell, Pharm.D., as Vice President of Regulatory Affairs
OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer. As a team of veterans with a track record of successful drug discovery and development, we are leveraging our proven structure-based drug design approach to create a robust pipeline of drug candidates that are designed to achieve optimal tolerability and efficacy. OnKure is currently developing OKI-219, a selective PI3KαH1047R inhibitor. In the evolving landscape of precision oncology, we believe an oncogene-targeting approach is key to discovering highly effective treatments for cancer patients with unmet medical needs.